4basebio (LON:4BB) Stock Price Down 2.2% - Should You Sell?

4basebio PLC (LON:4BB - Get Free Report) shares traded down 2.2% on Friday . The company traded as low as GBX 1,100 ($14.66) and last traded at GBX 1,100 ($14.66). 693 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,077 shares. The stock had previously closed at GBX 1,125 ($14.99).

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada reiterated an "outperform" rating and set a GBX 1,600 ($21.32) price target on shares of 4basebio in a research report on Thursday, March 13th.

4basebio Stock Performance

The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The company's 50-day moving average price is GBX 1,134.73 and its two-hundred day moving average price is GBX 1,198.45. The company has a market cap of £141.04 million, a P/E ratio of -1,411.54 and a beta of 1.09.

Insiders Place Their Bets

In related news, insider Amy Walker bought 1,151 shares of the firm's stock in a transaction on Friday, February 28th. The stock was bought at an average price of GBX 1,120 ($14.92) per share, with a total value of £12,891.20 ($17,176.82). Also, insider Heikki Lanckriet purchased 2,400 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were bought at an average price of GBX 1,205 ($16.06) per share, for a total transaction of £28,920 ($38,534.31). Corporate insiders own 68.44% of the company's stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.